FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079832124> ?p ?o ?g. }

• W2079832124 endingPage "618" @default.
• W2079832124 startingPage "609" @default.
• W2079832124 abstract "Purpose:153Sm-lexidronam has been used for the palliation of symptoms from painful bone metastases for years, while docetaxel has recently been shown to improve the survival of patients with hormone-refractory prostate cancer (HRPC). The first clinical experience with the combination of both treatment modalities is reported. Methods: Between 2005 and 2006, 12 patients with muliple bone metastases from HRPC were treated with a single application of 37 MBq/kg body weight 153Sm-lexidronam and 6 weekly infusions of 35 mg/m2 docetaxel. Data on survival, prostate-specific antigen (PSA) response, symptom palliation, toxicity, and scintigraphic follow-up are provided. Results: Mean follow-up was 11.4 (range, 1.1–25.8) months, overall 1-year survival was 48.6%, and median survival was 11.5 months. A PSA response of >50% was documented in 50% of patients. The average pain score (visual analog scale: 1–10) was reduced from 5.1 to 1.4 (p = 0.016) with decrease of ≥2 in 58.3% of patients. The average World Health Organization medication level dropped from 1.6 to 1.1 (p = 0.5). Overall toxicity was moderate, but 1 patient died due to neutropenic sepsis. Conclusions: Our analysis demonstrates feasibility and therapeutic potential for the combination treatment and merits prospective investigation. Further studies will be planned with respect to the potentially synergistic hematologic toxicity of bone-seeking radiopharmaceuticals and chemotherapy." @default.
• W2079832124 created "2016-06-24" @default.
• W2079832124 creator A5017841595 @default.
• W2079832124 creator A5020502124 @default.
• W2079832124 creator A5024035799 @default.
• W2079832124 creator A5030300404 @default.
• W2079832124 creator A5051748286 @default.
• W2079832124 creator A5071196966 @default.
• W2079832124 creator A5073780771 @default.
• W2079832124 creator A5084039770 @default.
• W2079832124 creator A5084114911 @default.
• W2079832124 creator A5089254227 @default.
• W2079832124 date "2008-10-01" @default.
• W2079832124 modified "2023-10-18" @default.
• W2079832124 title "Combining ¹⁵³Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience" @default.
• W2079832124 cites W1927196455 @default.
• W2079832124 cites W1935714962 @default.
• W2079832124 cites W1983514189 @default.
• W2079832124 cites W1986170691 @default.
• W2079832124 cites W1989792103 @default.
• W2079832124 cites W2004134686 @default.
• W2079832124 cites W2007745674 @default.
• W2079832124 cites W2010849237 @default.
• W2079832124 cites W2014746711 @default.
• W2079832124 cites W2038918152 @default.
• W2079832124 cites W2040136020 @default.
• W2079832124 cites W2057592449 @default.
• W2079832124 cites W2063548091 @default.
• W2079832124 cites W2080439368 @default.
• W2079832124 cites W2081463541 @default.
• W2079832124 cites W2104923745 @default.
• W2079832124 cites W2120292596 @default.
• W2079832124 cites W2125815927 @default.
• W2079832124 cites W2130342901 @default.
• W2079832124 cites W2134788484 @default.
• W2079832124 cites W2155679349 @default.
• W2079832124 cites W2156717291 @default.
• W2079832124 cites W4241174091 @default.
• W2079832124 doi "https://doi.org/10.1089/cbr.2008.0487" @default.
• W2079832124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18999933" @default.
• W2079832124 hasPublicationYear "2008" @default.
• W2079832124 type Work @default.
• W2079832124 sameAs 2079832124 @default.
• W2079832124 citedByCount "23" @default.
• W2079832124 countsByYear W20798321242012 @default.
• W2079832124 countsByYear W20798321242013 @default.
• W2079832124 countsByYear W20798321242014 @default.
• W2079832124 countsByYear W20798321242015 @default.
• W2079832124 countsByYear W20798321242016 @default.
• W2079832124 countsByYear W20798321242017 @default.
• W2079832124 countsByYear W20798321242019 @default.
• W2079832124 countsByYear W20798321242021 @default.
• W2079832124 countsByYear W20798321242022 @default.
• W2079832124 crossrefType "journal-article" @default.
• W2079832124 hasAuthorship W2079832124A5017841595 @default.
• W2079832124 hasAuthorship W2079832124A5020502124 @default.
• W2079832124 hasAuthorship W2079832124A5024035799 @default.
• W2079832124 hasAuthorship W2079832124A5030300404 @default.
• W2079832124 hasAuthorship W2079832124A5051748286 @default.
• W2079832124 hasAuthorship W2079832124A5071196966 @default.
• W2079832124 hasAuthorship W2079832124A5073780771 @default.
• W2079832124 hasAuthorship W2079832124A5084039770 @default.
• W2079832124 hasAuthorship W2079832124A5084114911 @default.
• W2079832124 hasAuthorship W2079832124A5089254227 @default.
• W2079832124 hasConcept C121332964 @default.
• W2079832124 hasConcept C121608353 @default.
• W2079832124 hasConcept C126322002 @default.
• W2079832124 hasConcept C126894567 @default.
• W2079832124 hasConcept C141071460 @default.
• W2079832124 hasConcept C142424586 @default.
• W2079832124 hasConcept C143998085 @default.
• W2079832124 hasConcept C188816634 @default.
• W2079832124 hasConcept C2776235491 @default.
• W2079832124 hasConcept C2776694085 @default.
• W2079832124 hasConcept C2780192828 @default.
• W2079832124 hasConcept C2781190966 @default.
• W2079832124 hasConcept C2781406297 @default.
• W2079832124 hasConcept C29730261 @default.
• W2079832124 hasConcept C71924100 @default.
• W2079832124 hasConcept C87355193 @default.
• W2079832124 hasConceptScore W2079832124C121332964 @default.
• W2079832124 hasConceptScore W2079832124C121608353 @default.
• W2079832124 hasConceptScore W2079832124C126322002 @default.
• W2079832124 hasConceptScore W2079832124C126894567 @default.
• W2079832124 hasConceptScore W2079832124C141071460 @default.
• W2079832124 hasConceptScore W2079832124C142424586 @default.
• W2079832124 hasConceptScore W2079832124C143998085 @default.
• W2079832124 hasConceptScore W2079832124C188816634 @default.
• W2079832124 hasConceptScore W2079832124C2776235491 @default.
• W2079832124 hasConceptScore W2079832124C2776694085 @default.
• W2079832124 hasConceptScore W2079832124C2780192828 @default.
• W2079832124 hasConceptScore W2079832124C2781190966 @default.
• W2079832124 hasConceptScore W2079832124C2781406297 @default.
• W2079832124 hasConceptScore W2079832124C29730261 @default.
• W2079832124 hasConceptScore W2079832124C71924100 @default.
• W2079832124 hasConceptScore W2079832124C87355193 @default.
• W2079832124 hasIssue "5" @default.
• W2079832124 hasLocation W20798321241 @default.

• next